# Somatostatin receptor 2

Source: https://onco.cc/targets/sstr2/  
OnCo record `sstr2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.

## Summary

Somatostatin receptor 2 is a G-protein-coupled receptor overexpressed on well-differentiated neuroendocrine tumours, which internalise bound somatostatin analogues and so can be both imaged and treated with the same peptide. 68Ga-DOTATATE PET (Netspot) and 177Lu-DOTATATE (Lutathera, NETTER-1 and NETTER-2) established the theranostic paradigm, in which a diagnostic scan selects patients for a matched radioligand. SSTR PET is positive in 80-90% of well-differentiated neuroendocrine tumours but lower in grade 3, and the receptor is also expressed in meningioma, 30-50% of small-cell lung cancer, and some breast cancers. Alpha-emitting 225Ac-DOTATATE (RYZ101) and 212Pb-DOTAMTATE are in phase 3, testing whether alpha particles outperform beta. The simple version is a hormone receptor that lets doctors see and treat neuroendocrine tumours with the same molecule.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: theranostic
- Symbol: SSTR2
- Class: surface-antigen
- Biology: G-protein-coupled receptor; also expressed in meningioma, small-cell lung cancer, and some breast cancers.
- Where found: Neuroendocrine tumours; Meningioma; Small-cell lung cancer (subset)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Somatostatin_receptor_2
- Wikipedia: https://en.wikipedia.org/wiki/Somatostatin_receptor_2

## Connected records

- biomarkers: [Somatostatin receptor expression by PET (SSTR-positive)](https://onco.cc/biomarkers/sstr-pet-expression/)
- cancers: [Esthesioneuroblastoma (olfactory neuroblastoma)](https://onco.cc/cancers/esthesioneuroblastoma/), [Grade 3 well-differentiated neuroendocrine tumour](https://onco.cc/cancers/grade-3-net/), [Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)](https://onco.cc/cancers/hereditary-ppgl/), [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://onco.cc/cancers/lung-net/), [Metastatic pheochromocytoma and paraganglioma](https://onco.cc/cancers/metastatic-ppgl/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://onco.cc/cancers/multiple-endocrine-neoplasia/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/), [Pheochromocytoma and paraganglioma (PPGL)](https://onco.cc/cancers/pheochromocytoma-paraganglioma/), [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/), [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [177Lu-edotreotide](https://onco.cc/drugs/itm-11/), [212Pb-DOTAMTATE](https://onco.cc/drugs/alphamedix/), [Actinium-225 DOTATATE](https://onco.cc/drugs/ryz101/), [CAM2029 (octreotide subcutaneous depot)](https://onco.cc/drugs/cam2029/), [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://onco.cc/drugs/ga68-dotatate/), [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/), [Paltusotine](https://onco.cc/drugs/paltusotine/), [Pasireotide](https://onco.cc/drugs/pasireotide/), [Somatostatin analogues (octreotide, lanreotide)](https://onco.cc/drugs/octreotide-lanreotide/)
- companies: [ITM Isotope Technologies Munich](https://onco.cc/companies/itm/), [Orano Med](https://onco.cc/companies/orano-med/), [Perspective Therapeutics](https://onco.cc/companies/perspective-therapeutics/), [POINT Biopharma](https://onco.cc/companies/point-biopharma/), [RadioMedix](https://onco.cc/companies/radiomedix/)
- technologies: [Auger-electron therapy](https://onco.cc/technologies/auger-electron-therapy/), [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/), [Peptide receptor radionuclide therapy (PRRT)](https://onco.cc/technologies/prrt/), [Radioligand plus DNA-repair inhibitor combinations](https://onco.cc/technologies/radionuclide-parp-combination/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://onco.cc/technologies/sstr-pet/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- trials: [COMPETE](https://onco.cc/trials/compete/), [NETTER-1](https://onco.cc/trials/netter-1/)
- pairings: [SSTR PET → PRRT](https://onco.cc/pairings/sstr-pet-to-prrt/)
- ideas: [SSTR antagonist radioligands to increase tumour dose](https://onco.cc/ideas/idea-net-antagonist-ligands/)
- targets: [Dopamine D2 receptor](https://onco.cc/targets/drd2/), [Tryptophan hydroxylase 1](https://onco.cc/targets/tph1/)
- roadmaps: [Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET](https://onco.cc/roadmaps/molecular-imaging-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)
- people: [Emily K. Bergsland](https://onco.cc/people/emily-bergsland/), [Jonathan R. Strosberg](https://onco.cc/people/jonathan-strosberg/), [Martyn E. Caplin](https://onco.cc/people/martyn-caplin/), [Simron Singh](https://onco.cc/people/simron-singh/)
- key papers: [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-netter-2-lancet-2024/)
- terms: [PRRT (peptide receptor radionuclide therapy)](https://onco.cc/terms/prrt-term/)
- institutions: [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/), [Holden Comprehensive Cancer Center, University of Iowa](https://onco.cc/institutions/iowa-holden/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://onco.cc/institutions/inselspital-bern/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://onco.cc/institutions/irst-meldola/), [Uppsala University Hospital / Uppsala University](https://onco.cc/institutions/uppsala-akademiska/)

---
JSON: https://onco.cc/api/v1/entities/sstr2.json